English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally (1). HCC capsules that develop during hepatocarcinogenesis are characteristic of nodular HCC (2). These capsules consist of peritumoral fibrosis and prominent sinusoids, and are observed in about 70% of nodular HCCs (3, 4). Therefore, the presence and identification of capsules are important for the non-invasive diagnosis of HCC. The United Network for Organ Sharing (UNOS)-Organ procurement transplant network (OPTN) system and the Liver Imaging Reporting and Data System (LI-RADS) include an encapsulated appearance as a feature of HCC (5, 6). Furthermore, the existence of an intact capsule is associated with better survival rates and lower recurrence rates after resection or ablative therapy (7, 8). Contrast-enhanced MRI using dynamic contrast enhanced T1-weighted gradient echo sequences is the most reliable technique for detecting HCC capsules (4, 9). Extracellular and hepatobiliary gadolinium-based contrast agents (gadoxetic acid; Primovist or Eovist; Bayer Healthcare, Berlin, Germany) are commonly used for liver MRI. However, since the pharmacokinetic and pharmacodynamics of these two contrast agents difValue of Image Subtraction for the Identification of Hepatocellular Carcinoma Capsule on Gadoxetic Acid-Enhanced MRI - MRI